Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
TransCode Therapeutics ( (RNAZ) ) just unveiled an announcement.
On September 30, 2025, TransCode Therapeutics, Inc. and Massachusetts General Hospital amended their Exclusive Patent License Agreement, originally dated October 26, 2018. The amendment, effective August 15, 2025, updates timelines and requirements for pre-sales of two patent families and increases milestone payments from $1,550,000 to $2,950,000 for each patent family, impacting the company’s financial commitments and strategic planning.
The most recent analyst rating on (RNAZ) stock is a Buy with a $280.00 price target. To see the full list of analyst forecasts on TransCode Therapeutics stock, see the RNAZ Stock Forecast page.
Spark’s Take on RNAZ Stock
According to Spark, TipRanks’ AI Analyst, RNAZ is a Underperform.
TransCode Therapeutics, as an early-stage biotech firm, presents a high-risk investment profile with significant financial challenges. The lack of revenue and increasing losses, coupled with negative equity, highlight financial instability. Technical indicators suggest continued downward pressure on the stock. The absence of a favorable valuation further impacts its attractiveness. Investors should be cautious given the speculative nature and financial health of the company.
To see Spark’s full report on RNAZ stock, click here.
More about TransCode Therapeutics
TransCode Therapeutics, Inc. operates in the biopharmaceutical industry, focusing on developing therapeutic products and processes. The company is engaged in advancing treatments that target specific genetic components, with a market focus on innovative healthcare solutions.
Average Trading Volume: 89,662
Technical Sentiment Signal: Sell
Current Market Cap: $8.85M
For detailed information about RNAZ stock, go to TipRanks’ Stock Analysis page.